Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT03723928
S1703, Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread...
-
NCT05812807
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT06760637
An Interventional, Open-label, Randomized, Multicenter Phase 3 Study of PF-07220060 plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants over 18 Years with Hormone Receptor (HR)-Positive, HER2-Negatrive Advanced/Metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced/Metastatic Disease
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of the study is to evaluate whether PF-07220060 plus letrozole can improve clinical outcomes relative to cyclin-dependent kinase (CDK) 4/6 inhibitor (CDK4/6i) (investigator’s choice...
-
NCT05616104
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Study)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to create a large-scale, population-based database. This database will match health information with genome data to potentially identify new gene associations in breast...
-
NCT5812807
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT06188559
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...